Pacific Biosciences of California, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Oene Mark Van, See Remarks of Pacific Biosciences Of California, Inc., reported multiple transactions in common stock on August 10, 2026.
NASDAQ
Pacific Biosciences director Marshall Mohr was granted an option to purchase 223,492 shares of common stock.
NASDAQ
Director Christopher Gibson was granted 74,497 stock options in Pacific Biosciences of California, Inc. as part of standard compensation.
NASDAQ
Director Christopher M. Smith was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.
NASDAQ
Director Hannah Valantine was granted 223,492 stock options in Pacific Biosciences of California, Inc. on June 3, 2026.
NASDAQ
Pacific Biosciences director Randall S. Livingston was granted 223,492 stock options as part of standard equity compensation.
NASDAQ
Pacific Biosciences of California director William W. Ericson was granted 223,492 stock options as part of his compensation.
NASDAQ
Pacific Biosciences director John F. Milligan was granted 223,492 stock options as part of his compensation package.
NASDAQ
Director Kathy Ordonez was granted 223,492 stock options in Pacific Biosciences of California, Inc. as part of standard compensation.
NASDAQ
James R. Gibson II, CFO of Pacific Biosciences of California, Inc., sold 88,185 shares to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Christopher Gibson joins Pacific Biosciences of California's Board of Directors, receiving restricted stock units and stock options.
NASDAQ
Pacific Biosciences CEO Christian O. Henry sold 12,497 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Pacific Biosciences of California's COO, Mark Van Oene, sold 6,504 shares of common stock to cover tax withholding obligations.
NASDAQ
Michele Farmer, Chief Accounting Officer of Pacific Biosciences, sold 2,979 shares of common stock to cover tax withholding obligations.
NASDAQ
Pacific Biosciences of California granted 89,835 Restricted Stock Units and 179,670 stock options to its Chief Accounting Officer, Michele Farmer.
NASDAQ
Pacific Biosciences of California's CFO, James R. Gibson II, was granted 333,848 Restricted Stock Units and options to purchase 667,696 shares.
NASDAQ
Pacific Biosciences of California's Chief Operating Officer, Mark Van Oene, was granted 500,000 Restricted Stock Units and options for 1,000,000 shares of common stock.
NASDAQ
Pacific Biosciences CEO Christian O. Henry acquired 920,810 Restricted Stock Units and 1,841,621 stock options, aligning interests with shareholders.
NASDAQ
Pacific Biosciences COO Mark Van Oene sold 184,897 shares of common stock across two transactions in February 2026 to cover tax withholding obligations.
NASDAQ
Pacific Biosciences CEO Christian Henry sold 472,667 shares of common stock across two transactions to cover tax withholding obligations related to the vesting of restricted stock units.
NASDAQ
Pacific Biosciences' Chief Accounting Officer, Michele Farmer, sold 50,167 shares of common stock across two transactions to cover tax withholding obligations from restricted stock unit vesting.
NASDAQ
Pacific Biosciences' Chief Operating Officer, Mark Van Oene, sold 26,836 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.
NASDAQ
Pacific Biosciences of California, Inc. Director Marshall Mohr was granted 65,000 stock options with an exercise price of $1.03, vesting over one year.
NASDAQ
Pacific Biosciences of California, Inc. director Randall S. Livingston was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.
NASDAQ
Pacific Biosciences of California, Inc. director Kathy Ordonez was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.
NASDAQ
Pacific Biosciences of California, Inc. (PACB) Director Lucy Shapiro was granted 65,000 stock options with an exercise price of $1.03, vesting over one year.
NASDAQ
Pacific Biosciences of California, Inc. director William W. Ericson was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.
NASDAQ
John F. Milligan, a Director at Pacific Biosciences of California, Inc., acquired 65,000 stock options with an exercise price of $1.03, vesting over one year.
NASDAQ
Pacific Biosciences of California, Inc. director Hannah Valantine was granted 65,000 stock options with an exercise price of $1.03, vesting monthly over one year.
NASDAQ
Pacific Biosciences of California, Inc. Director Christopher M. Smith was granted 32,500 stock options with an exercise price of $1.03, vesting over one year.